NCT05536791View on ClinicalTrials.gov

A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

November 24, 2022

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions
Venous Thromboembolism
Interventions
DRUG

Dabigatran Etexilate (DE)

Dabigatran Etexilate (DE)

Trial Locations (6)

13353

Charité - Universitätsmedizin Berlin, Berlin

28009

Hospital Materno Infantil Gregorio Marañón, Madrid

6525 GL

Radboud Universitair Medisch Centrum, Nijmegen

3584 CX

Universitair Medisch Centrum Utrecht, Utrecht

08950

Hospital Sant Joan de Déu, Barcelona

171 76

Karolinska Universitetssjukhuset, Stockholm

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05536791 - A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot | Biotech Hunter | Biotech Hunter